company background image
301246 logo

Hubei Hongyuan Pharmaceutical Technology SZSE:301246 Stock Report

Last Price

CN¥14.57

Market Cap

CN¥5.8b

7D

-4.8%

1Y

-42.8%

Updated

21 Dec, 2024

Data

Company Financials

Hubei Hongyuan Pharmaceutical Technology Co., Ltd.

SZSE:301246 Stock Report

Market Cap: CN¥5.8b

301246 Stock Overview

Engages in the production and sale of pharmaceutical products in China and internationally. More details

301246 fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health5/6
Dividends1/6

My Notes

Capture your thoughts, links and company narrative

Hubei Hongyuan Pharmaceutical Technology Co., Ltd. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Hubei Hongyuan Pharmaceutical Technology
Historical stock prices
Current Share PriceCN¥14.57
52 Week HighCN¥26.30
52 Week LowCN¥10.58
Beta0
1 Month Change-11.48%
3 Month Change34.16%
1 Year Change-42.80%
3 Year Changen/a
5 Year Changen/a
Change since IPO-65.27%

Recent News & Updates

Does Hubei Hongyuan Pharmaceutical Technology (SZSE:301246) Have A Healthy Balance Sheet?

Dec 18
Does Hubei Hongyuan Pharmaceutical Technology (SZSE:301246) Have A Healthy Balance Sheet?

Subdued Growth No Barrier To Hubei Hongyuan Pharmaceutical Technology Co., Ltd. (SZSE:301246) With Shares Advancing 38%

Oct 08
Subdued Growth No Barrier To Hubei Hongyuan Pharmaceutical Technology Co., Ltd. (SZSE:301246) With Shares Advancing 38%

Recent updates

Does Hubei Hongyuan Pharmaceutical Technology (SZSE:301246) Have A Healthy Balance Sheet?

Dec 18
Does Hubei Hongyuan Pharmaceutical Technology (SZSE:301246) Have A Healthy Balance Sheet?

Subdued Growth No Barrier To Hubei Hongyuan Pharmaceutical Technology Co., Ltd. (SZSE:301246) With Shares Advancing 38%

Oct 08
Subdued Growth No Barrier To Hubei Hongyuan Pharmaceutical Technology Co., Ltd. (SZSE:301246) With Shares Advancing 38%

Hubei Hongyuan Pharmaceutical Technology Co., Ltd.'s (SZSE:301246) P/S Still Appears To Be Reasonable

Aug 23
Hubei Hongyuan Pharmaceutical Technology Co., Ltd.'s (SZSE:301246) P/S Still Appears To Be Reasonable

Hubei Hongyuan Pharmaceutical Technology's (SZSE:301246) Soft Earnings Are Actually Better Than They Appear

Apr 29
Hubei Hongyuan Pharmaceutical Technology's (SZSE:301246) Soft Earnings Are Actually Better Than They Appear

Getting In Cheap On Hubei Hongyuan Pharmaceutical Technology Co., Ltd. (SZSE:301246) Is Unlikely

Mar 14
Getting In Cheap On Hubei Hongyuan Pharmaceutical Technology Co., Ltd. (SZSE:301246) Is Unlikely

Shareholder Returns

301246CN PharmaceuticalsCN Market
7D-4.8%-1.9%-1.2%
1Y-42.8%-1.8%11.8%

Return vs Industry: 301246 underperformed the CN Pharmaceuticals industry which returned -1.8% over the past year.

Return vs Market: 301246 underperformed the CN Market which returned 11.8% over the past year.

Price Volatility

Is 301246's price volatile compared to industry and market?
301246 volatility
301246 Average Weekly Movement8.5%
Pharmaceuticals Industry Average Movement7.4%
Market Average Movement8.7%
10% most volatile stocks in CN Market12.8%
10% least volatile stocks in CN Market5.7%

Stable Share Price: 301246 has not had significant price volatility in the past 3 months compared to the CN market.

Volatility Over Time: 301246's weekly volatility (8%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
20022,075Shuangxi Xuwww.hbhypharm.com

Hubei Hongyuan Pharmaceutical Technology Co., Ltd., together with its subsidiaries, engages in the production and sale of pharmaceutical products in China and internationally. It provides active pharmaceutical ingredients, such as metronidazole, benzoyl metronidazole, dimetrizole, and acyclovir; pharmaceutical intermediates, including glyoxylic acid, 2-methyl imidazole, 2-methyl-5-nitroimidazole, sulfate, triamine, diacetyl guanine, guanine, and diacetylacyclovir; organic chemical raw materials comprising fluoride salts, glyoxal, and oxalic acid; and new energy materials consisting of lithium hexafluorophosphate. The company was founded in 2002 and is headquartered in Huanggang, China.

Hubei Hongyuan Pharmaceutical Technology Co., Ltd. Fundamentals Summary

How do Hubei Hongyuan Pharmaceutical Technology's earnings and revenue compare to its market cap?
301246 fundamental statistics
Market capCN¥5.80b
Earnings (TTM)CN¥27.01m
Revenue (TTM)CN¥1.82b

214.7x

P/E Ratio

3.2x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
301246 income statement (TTM)
RevenueCN¥1.82b
Cost of RevenueCN¥1.64b
Gross ProfitCN¥178.98m
Other ExpensesCN¥151.97m
EarningsCN¥27.01m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)0.068
Gross Margin9.84%
Net Profit Margin1.49%
Debt/Equity Ratio8.3%

How did 301246 perform over the long term?

See historical performance and comparison

Dividends

0.3%

Current Dividend Yield

74%

Payout Ratio

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/21 07:56
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Hubei Hongyuan Pharmaceutical Technology Co., Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution